Edition:
India

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

20.35USD
2 Dec 2016
Change (% chg)

$0.26 (+1.29%)
Prev Close
$20.09
Open
$20.14
Day's High
$20.55
Day's Low
$20.04
Volume
2,130,713
Avg. Vol
2,300,100
52-wk High
$24.78
52-wk Low
$15.68

BSX.N

Chart for BSX.N

About

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP),... (more)

Overall

Beta: 1.12
Market Cap(Mil.): $29,221.59
Shares Outstanding(Mil.): 1,361.68
Dividend: --
Yield (%): --

Financials

BRIEF-Nevro files lawsuit for patent infringement against Boston Scientific in the U.S.

* Nevro files lawsuit for patent infringement against Boston Scientific in the U.S.

29 Nov 2016

BRIEF-Boston Scientific acquires tissue resection device from Distal Access

* Boston Scientific Corp- specific terms of transaction were not disclosed

15 Nov 2016

BRIEF-Boston Scientific's unit Falcon Merger extends offer for all shares of EndoChoice Holdings

* Says unit, Falcon Merger Corp has extended its previously announced tender offer for all shares of EndoChoice Holdings

04 Nov 2016

BRIEF-Boston Scientific reports acquisition of the Lumenr tissue retractor system

* Boston Scientific announces acquisition of the lumenr tissue retractor system

03 Nov 2016

RPT-UPDATE 1-Boston Scientific lifts 2016 revenue forecast after beat

Oct 26 Boston Scientific Corp's quarterly revenue beat analysts' estimates, boosted by higher demand for its heart devices, and the medical device maker raised its full-year forecast again.

26 Oct 2016

BRIEF-Boston Scientific Q3 GAAP EPS $0.17

* Q4 earnings per share view $0.29, revenue view $2.15 billion -- Thomson Reuters I/B/E/S

26 Oct 2016

Medical device maker Boston Scientific's net sales rise 11.5 pct

Oct 26 Boston Scientific Corp reported an 11.5 percent rise in quarterly net sales, boosted by higher demand for its heart devices.

26 Oct 2016

BRIEF-Ian Meredith to join Boston Scientific as executive VP, global chief medical officer

* Professor Ian Meredith to join Boston Scientific as executive vice president and global chief medical officer Source text for Eikon: Further company coverage:

10 Oct 2016

BRIEF-Boston Scientific commences cash tender offer for all shares of EndoChoice for $8.00 per share in cash

* Boston Scientific commences cash tender offer for all shares of EndoChoice for $8.00 per share in cash

07 Oct 2016

BRIEF-EndoChoice holdings agreement with Boston Scientific provides termination fee of $7.95 million under certain circumstances

* Agreement with Boston Scientific provides termination fee of $7.95 million under certain circumstances Source text for Eikon: Further company coverage:

27 Sep 2016

Competitors

  Price Chg
Abbott Laboratories (ABT.N) $37.90 +0.30
St. Jude Medical, Inc. (STJ.N) $79.02 +0.24
Medtronic PLC (MDT.N) $72.01 +0.13

Earnings vs. Estimates